price
updat fy revenu estim
oper margin ep
exhibit estim revenu op margin line-with high end
guidanc weve updat long term temporari mechan circulatori
support tmc model reflect greater tmc penetr cardiogen
shock faster eros iabp dcf base price target
thesi outlin recent note link weve identifi larg
us patient popul like benefit tmc weve identifi non-
overlap patient popul exhibit view support
us market circa cy cy estim us cardiogen
shock admiss tmc penetr usag still domin
ineffect balloon pump estim high risk pci
either systol heart failur chronic kidney diseas extend length
stay without cardiogen shock tmc penetr
incid acut kidney injuri high risk subgroup
grow bodi evid suggest impella protect kidney function
link weve identifi anoth larg at-risk popul ami patient
dont receiv pci dont cardiogen shock either acut
systol heart failur acut kidney injuri extend length stay
group may approxim patient tmc penetr final
larg group admiss acut systol heart failur
without cardiogen shock pci ami larg group admiss
either acut kidney injuri extend length stay
almost total relianc drug therapi inclus over-reli inotrop
virtual tmc much evid develop remain believ
us market impella-lik devic reach cy
valuat risk price target dcf base predic
explicit model abmd fy termin year assum
corpor revenu ex-u oper margin
assum discount rate termin growth factor given high
oper margin structur compani suffici cash readili
avail technolog acquisit princip risk thesi
evid develop adjac segment ami w/o cs pci acut
systol heart failur without cs pci ami may develop curtail
harder envis final abmd strong valuat reflect
long tail opportun short term miss rel street expect
tr target
page
strh estimatesabmdconsensusstrh vs consensu cc est us us impella revenu impella product statementstrh estimatesabmdconsensusstrh vs consensu cc adjust incl incom adj estimatesabmdconsensusstrh vs consensusmargin expens margin adjust incl inc
nation inpati sampl ni healthcar util project hcup agenc healthcar
research qualiti ahrq compani file strh estim
page
compound-annual-growth-rate shockc w/o ami ami w/o pci w/o ami w/o cshigh risk sub-groupsshf w/o ckd w/o lo ckd w/o lo lo day w/o ckd lo w/o shf w/o lo lo day w/o day w/o shf w/o high pci w/o pci w/o w/o cs w/o pcihigh risk sub-groupsashf w/o aki w/o lo aki w/o lo lo day w/o aki lo w/o shf w/o lo day lo day w/o day w/o ashf w/o high risk ami w/o cs w/o ami w/o cs w/o w/o ami w/o cs w/o pcihigh risk sub-groupsaki w/o lo day day w/o lo day high risk w/o ami cs pci aki lo ashf w/o ami w/o cs w/o model patient higher risk inc
exhibit us tmc adopt assumpt segment
nation inpati sampl ni healthcar util project hcup agenc healthcar
research qualiti ahrq compani file strh estim
page
compound-annual-growth-rate shockisol w/o csisol w/o cs pciisol w/o cs pci amiisol indicationsisol tmcsisol shareisol asp patient inc
page
million except impella ou impella revenu total impella product servic total product fund total gross research total oper oper incom total incom expens pre-tax tax paid tax incom ep average share total reconciliations- net incom ep margin margin analysi yoy us impella impella impella revenu impella product impella product revenu revenu revenu oper incom incom abiom inc
 base danver
result proprietari databas analys believ impella-lik devic us
market opportun present larg opportun unlik
measur competit valuat also augment high intrins profit
impella revenu gross margin north
valuat risk
price target dcf base predic explicit model abmd fy
termin year assum corpor revenu ex-u oper
margin assum discount rate termin growth factor given high oper
margin structur compani suffici cash readili avail technolog acquisit
princip risk thesi evid develop adjac segment ami w/o cs
pci acut systol heart failur without cs pci ami may develop curtail market
opportun addit competit encroach may come faster harder envis
final abmd strong valuat reflect long tail opportun short term miss rel
street expect could caus abrupt pull-back
compani mention note
bruce nudel herebi certifi view express research report accur reflect
person view subject compani secur also certifi
receiv direct indirect compens exchang express specif
recommend report
